Aetna and Moffitt Cancer Center Form Announce Collaboration to Create an Oncology Medical Home
Apr 16 15
Moffitt Cancer Center and Aetna announced a collaboration to create an oncology medical home that is designed to improve the care experience for cancer patients. Within an oncology medical home model, teams of cancer specialists collectively provide for a patient’s health care when he or she has a cancer diagnosis. The model will give Moffitt the responsibility to arrange for appropriate care that is continuous and proactive. The model is part of a strategic direction to transition from fee-for-service medicine to value-based payment. Value-based arrangements are emerging as a solution to address rising health care costs, clinical inefficiency and duplication of services, and to make it easier for people to get the care they need. In value-based models, doctors and hospitals are paid for helping keep people healthy and for improving the health of those who have chronic conditions in an evidence-based, cost-effective way.
Moffitt Cancer Center Appoints Bryan Glazer to National Board of Advisors
Jan 6 15
Tampa Bay Buccaneers' Co-Chairman Bryan Glazer has been appointed to Moffitt Cancer Center's national Board of Advisors. Members of Moffitt's Board of Advisors act as ambassadors for the cancer center and provide expertise and counsel on cancer center issues. Glazer oversees day-to-day operations of the Bucs franchise. In addition, he played a role in the construction of Raymond James Stadium, securing Super Bowls in Tampa in 2001 and 2009, and the completion of the team's training facility in 2006.
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases
Nov 17 14
Moffitt Cancer Center announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases. Working toward making the treatment available to patients, Moffitt and Celgene Corporation have entered into a licensing agreement that gives Celgene the exclusive rights to the novel, investigational MDS therapy. The agents, developed by Alan F. List, M.D., Moffitt CEO and president, and Sheng Wei, M.D., senior member of Moffitt's Immunology Program, also has potential applications for autoimmune diseases, inflammation and enhancement of anti-cancer immune responses. The researchers at Moffitt discovered a strong linkage between inflammatory pathways, tumor microenvironment, innate immunity and the development of MDS. This led to the development of the licensed technologies, which could potentially improve treatments for MDS patients. Under the agreement, Celgene has the option to partner on five additional scientific programs, which Moffitt may elect to pursue, including immunotherapy and cell signaling. Financial considerations were not disclosed.